Human genetics of tuberculosis: A long and winding road

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1645, 2014, Pages

  Abel, Laurent ^a,b,c   El Baghdadi, Jamila ^d   Bousfiha, Ahmed Aziz ^e   Casanova, Jean Laurent ^a,b,c   Schurr, Erwin ^f  

^a IMAGINE INSTITUTE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ROCKEFELLER UNIVERSITY   (United States)

^d MILITARY HOSPITAL MOHAMMED V   (Morocco)

^e IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^f RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Complex genetic predisposition; Genetic variant; Latent tuberculosis infection; Mendelian predisposition; Primary tuberculosis; Pulmonary tuberculosis

Indexed keywords

AGE; BACTERIAL DISEASE; GENETIC VARIATION; IMMUNITY; PATHOGEN; POPULATION GENETICS; TUBERCULOSIS;

EID: 84900330164     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0428     Document Type: Review

References (127)

1. WHO. 2013 Global tuberculosis report. Geneva, Switzerland: World Health Organization.
2. Stewart GR, Robertson BD, Young DB. 2003 Tuberculosis: a problem with persistence. Nat. Rev. Microbiol. 1, 97-105. (doi:10.1038/nrmicro749)
3. Zumla A, Raviglione M, Hafner R, von Reyn CF. 2013 Tuberculosis. N Engl. J. Med. 368, 745-755. (doi:10.1056/NEJMra1200894)
4. Cruz AT, Starke JR. 2007 Clinical manifestations of tuberculosis in children. Paediatr. Respir. Rev. 8, 107-117. (doi:10.1016/j.prrv.2007.04.008)
5. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. 2006 Childhood pulmonary tuberculosis: old wisdom and new challenges. Am. J. Respir. Crit. Care Med. 173, 1078-1090. (doi:10.1164/rccm. 200511-1809SO)
6. Ernst JD. 2012 The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12, 581-591. (doi:10.1038/nri3259)
7. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013 The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475-527. (doi:10.1146/annurev-immunol-032712-095939)
8. Casanova JL, Abel L. 2002 Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581-620. (doi:10.1146/ annurev.immunol.20.081501.125851)
9. Dubos RJ, Dubos J. 1952 The white plague; tuberculosis, man and society, 1st edn, p. 277. Boston, MA: Little Brown.
10. Puffer R. 1944 Familial susceptibility to tuberculosis; its importance as a public health problem, p. 106. Cambridge, MA: Harvard University Press.
11. Kallmann FJ, Reisner D. 1943 Twin studies on the significance of genetic factors in tuberculosis. Am. Rev. Tuberc. 47, 549-574.
12. Stead WW. 1997 The origin and erratic global spread of tuberculosis. How the past explains the present and is the key to the future. Clin. Chest Med. 18, 65-77. (doi:10.1016/S0272-5231(05) 70356-7)
13. Stead WW. 1992 Genetics and resistance to tuberculosis. Could resistance be enhanced by genetic engineering? Ann. Intern. Med. 116, 937-941. (doi:10.7326/0003-4819-116-11-937)
14. Stead WW, Senner JW, Reddick WT, Lofgren JP. 1990 Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N. Engl. J. Med. 322, 422-427. (doi:10.1056/ NEJM199002153220702)
15. Di Pietrantonio T, Schurr E. 2005 Mouse models for the genetic study of tuberculosis susceptibility. Brief Funct. Genomics Proteomics 4, 277-292. (doi:10. 1093/bfgp/4.3.277)
16. Fortin A, Abel L, Casanova JL, Gros P. 2007 Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis. Annu. Rev. Genomics Hum. Genet. 8, 163-192. (doi:10.1146/annurev.genom.8.080706.092315)
17. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. 1993 Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73, 469-485. (doi:10.1016/0092-8674(93) 90135-D)
18. Cooper AM. 2009 Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422. (doi:10.1146/annurev.immunol.021908.132703)
19. North RJ, Jung YJ. 2004 Immunity to tuberculosis. Annu. Rev. Immunol. 22, 599-623. (doi:10.1146/ annurev.immunol.22.012703.104635)
20. Cooper AM. 2009 T cells in mycobacterial infection and disease. Curr. Opin. Immunol. 21, 378-384. (doi:10.1016/j.coi.2009.06.004)
21. Suthar AB et al. 2012 Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 9, e1001270. (doi:10.1371/journal.pmed.1001270)
22. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, 1098-1104. (doi:10.1056/NEJMoa011110)
23. Alcais A, Fieschi C, Abel L, Casanova JL. 2005 Tuberculosis in children and adults: two distinct genetic diseases. J. Exp. Med. 202, 1617-1621. (doi:10.1084/jem.20052302)
24. Boisson-Dupuis S et al. 2011 IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS ONE 6, e18524. (doi:10.1371/journal.pone.0018524)
25. Reichman LB. 1979 Tuberculin skin testing. The state of the art. Chest 76, 764-770. (doi:10.1378/ chest.76.6.764)
26. Richeldi L. 2006 An update on the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care Med. 174, 736-742. (doi:10.1164/rccm.200509-1516PP)
27. Gallant CJ et al. 2010 Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest 137, 1071-1077. (doi:10.1378/ chest.09-1852)
28. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. 2003 Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int. J. Tuberc. Lung Dis. 7, S384-S390.
29. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. 2000 Outcomes of contact investigations of infectious tuberculosis patients. Am. J. Respir. Crit. Care Med. 162, 2033-2038. (doi:10.1164/ajrccm.162.6.2004022)
30. Jepson A, Fowler A, Banya W, Singh M, Bennett S, Whittle H, Hill AV. 2001 Genetic regulation of acquired immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa. Infect. Immun. 69, 3989-3994. (doi:10.1128/IAI.69.6.3989-3994.2001)
31. Sepulveda RL, Heiba IM, King A, Gonzalez B, Elston RC, Sorensen RU. 1994 Evaluation of tuberculin reactivity in BCG-immunized siblings. Am. J. Respir. Crit. Care Med. 149, 620-624. (doi:10.1164/ajrccm. 149.3.8118628)
32. Cobat A et al. 2010 High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J. Infect Dis. 201, 15-19. (doi:10.1086/648611)
33. Cobat A, Barrera LF, Henao H, Arbelaez P, Abel L, Garcia LF, Schurr E, Alcais A. 2012 Tuberculin skin test reactivity is dependent on host genetic background in Colombian tuberculosis household contacts. Clin. Infect. Dis. 54, 968-971. (doi:10. 1093/cid/cir972)
34. Stein CM, Guwatudde D, Nakakeeto M, Peters P, Elston RC, Tiwari HK, Mugerwa R, Whalen CC. 2003 Heritability analysis of cytokines as intermediate phenotypes of tuberculosis. J. Infect Dis. 187, 1679-1685. (doi:10.1086/375249)
35. Tao L, Zalwango S, Chervenak K, Thiel B, Malone LL, Qiu F, Mayanja-Kizza H, Boom WH, Stein CM. 2013 Genetic and shared environmental influences on interferon-gamma production in response to Mycobacterium tuberculosis antigens in a Ugandan population. Am. J. Trop. Med. Hyg. 89, 169-173. (doi:10.4269/ajtmh.12-0670)
36. Thye T et al. 2009 IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoS ONE 4, e5420. (doi:10.1371/ journal.pone.0005420)
37. Zembrzuski VM, Basta PC, Callegari-Jacques SM, Santos RV, Coimbra CE, Salzano FM, Hutz MH. 2010 Cytokine genes are associated with tuberculin skin test response in a native Brazilian population. Tuberculosis (Edinb) 90, 44-49. (doi:10.1016/j. tube.2009.11.002)
38. Stein CM et al. 2008 Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS ONE 3, e4094. (doi:10.1371/journal.pone.0004094)
39. Cobat A et al. 2009 Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 206, 2583-2591. (doi:10. 1084/jem.20090892)
40. Cobat A et al. 2013 Identification of a major locus, TNF1, that controls BCG-triggered tumor necrosis factor production by leukocytes in an area hyperendemic for tuberculosis. Clin. Infect. Dis. 57, 963-970. (doi:10.1093/cid/cit438)
41. Ranke KE. 1910 Diagnose und epidemiologie des lungentuberculose des kindes. Arch. Kinderheilkd 54, 279-306.
42. Maartens G, Wilkinson RJ. 2007 Tuberculosis. Lancet 370, 2030-2043. (doi:10.1016/S0140-6736(07) 61262-8)
43. WHO. 2011 Global tuberculosis control. Geneva, Switzerland: WHO/HTM/TB/2011.
44. Reichenbach J, Rosenzweig S, Doffinger R, Dupuis S, Holland SM, Casanova JL. 2001 Mycobacterial diseases in primary immunodeficiencies. Curr. Opin. Allergy Clin. Immunol. 1, 503-511. (doi:10.1097/ 00130832-200112000-00003)
45. Bustamante J et al. 2007 BCG-osis and tuberculosis in a child with chronic granulomatous disease. J. Allergy Clin. Immunol. 120, 32-38. (doi:10.1016/ j.jaci.2007.04.034)
46. Lau YL, Chan GC, Ha SY, Hui YF, Yuen KY. 1998 The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin. Infect. Dis. 26, 226-227. (doi:10.1086/517036)
47. Lee PP et al. 2008 Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr. Infect Dis. J 27, 224-230. (doi:10.1097/INF. 0b013e31815b494c)
48. Martire B et al. 2008 Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin. Immunol. 126, 155-164. (doi:10.1016/j.clim.2007.09.008)
49. Movahedi M et al. 2004 Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int. Arch. Allergy Immunol. 134, 253-259. (doi:10.1159/ 000078774)
50. Conti et al. Submitted. Mycobacterial diseases in 71 patients with chronic granulomatous disease.
51. Al-Muhsen S, Casanova JL. 2008 The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J. Allergy Clin. Immunol. 122, 1043-1051; quiz 1052-1043. (doi:10.1016/j. jaci.2008.10.037)
52. Bogunovic D et al. 2012 Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 337, 1684-1688. (doi:10.1126/science.1224026)
53. Bustamante J et al. 2011 Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat. Immunol. 12, 213-221. (doi:10.1038/ni.1992)
54. Filipe-Santos O et al. 2006 Inborn errors of IL-12/ 23-and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18, 347-361. (doi:10.1016/j.smim.2006. 07.010)
55. Hambleton S et al. 2011 IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365, 127-138. (doi:10.1056/NEJMoa1100066)
56. Casanova JL, Abel L. 2013 The genetic theory of infectious diseases: a brief history and selected illustrations. Annu. Rev. Genomics Hum. Genet. 14, 215-243. (doi:10.1146/annurev-genom-091212-153448)
57. Dorman SE et al. 2004 Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364, 2113-2121. (doi:10.1016/S0140-6736(04) 17552-1)
58. Sasaki Y, Nomura A, Kusuhara K, Takada H, Ahmed S, Obinata K, Hamada K, Okimoto Y, Hara T. 2002 Genetic basis of patients with bacille Calmette-Guerin osteomyelitis in Japan: identification of dominant partial interferon-gamma receptor 1 deficiency as a predominant type. J. Infect Dis. 185, 706-709. (doi:10.1086/339011)
59. Picard C et al. 2002 Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am. J. Hum. Genet. 70, 336-348. (doi:10.1086/338625)
60. Jouanguy E et al. 1997 Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J. Clin. Invest. 100, 2658-2664. (doi:10.1172/JCI119810)
61. de Beaucoudrey L et al. 2010 Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89, 381-402. (doi:10.1097/MD.0b013e3181fdd832)
62. Altare F et al. 2001 Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J. Infect Dis. 184, 231-236. (doi:10.1086/321999)
63. Caragol I et al. 2003 Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin. Infect. Dis. 37, 302-306. (doi:10. 1086/375587)
64. Ozbek N, Fieschi C, Yilmaz BT, de Beaucoudrey L, Demirhan B, Feinberg J, Bikmaz YE, Casanova JL. 2005 Interleukin-12 receptor beta 1 chain deficiency in a child with disseminated tuberculosis. Clin. Infect. Dis. 40, e55-e58. (doi:10.1086/427879)
65. Myers FB, Henrikson RH, Bone J, Lee LP. 2013 A handheld point-of-care genomic diagnostic system. PLoS ONE 8, e70266. (doi:10.1371/journal.pone. 0070266)
66. Roberts JD et al. 2012 Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379, 1705-1711. (doi:10.1016/S0140-6736(12)60161-5)
67. Alangari AA, Al-Zamil F, Al-Mazrou A, Al-Muhsen S, Boisson-Dupuis S, Awadallah S, Kambal A, Casanova JL. 2011 Treatment of disseminated mycobacterial infection with high-dose IFN-gamma in a patient with IL-12Rbeta1 deficiency. Clin. Dev. Immunol. 2011, 691956. (doi:10.1155/2011/691956)
68. Vynnycky E, Fine PE. 2000 Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152, 247-263. (doi:10.1093/aje/ 152.3.247)
69. Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO, Andersen AB. 2003 Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J. Infect Dis. 188, 1032-1039. (doi:10. 1086/378240)
70. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. 2010 Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann. N Y Acad. Sci. 1214, 18-33. (doi:10.1111/j.1749-6632.2010.05834.x)
71. Comas I et al. 2013 Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45, 1176-1182. (doi:10.1038/ng.2744)
72. Gagneux S. 2012 Host-pathogen coevolution in human tuberculosis. Phil. Trans. R. Soc. B 367, 850-859. (doi:10.1098/rstb.2011.0316)
73. Azad AK, Sadee W, Schlesinger LS. 2012 Innate immune gene polymorphisms in tuberculosis. Infect. Immun. 80, 3343-3359. (doi:10.1128/IAI.00443-12)
74. Moller M, de Wit E, Hoal EG. 2010 Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol. Med. Microbiol. 58, 3-26. (doi:10.1111/j.1574-695X.2009.00600.x)
75. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. 1998 Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl. J. Med. 338, 640-644. (doi:10. 1056/NEJM199803053381002)
76. Li HT, Zhang TT, Zhou YQ, Huang QH, Huang J. 2006 SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int. J. Tuberc. Lung Dis. 10, 3-12.
77. Greenwood CM, Fujiwara TM, Boothroyd LJ, Miller MA, Frappier D, Fanning EA, Schurr E, Morgan K. 2000 Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am. J. Hum. Genet. 67, 405-416. (doi:10.1086/303012)
78. Malik S et al. 2005 Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease. Proc. Natl Acad. Sci. USA 102, 12 183-12 188. (doi:10. 1073/pnas.0503368102)
79. Alcais A et al. 2007 Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nat. Genet. 39, 517-522. (doi:10.1038/ng2000)
80. Alter A et al. 2011 Human leukocyte antigen class I region single-nucleotide polymorphisms are associated with leprosy susceptibility in Vietnam and India. J. Infect Dis. 203, 1274-1281. (doi:10. 1093/infdis/jir024)
81. Baghdadi JE et al. 2006 An autosomal dominant major gene confers predisposition to pulmonary tuberculosis in adults. J. Exp. Med. 203, 1679-1684. (doi:10.1084/jem.20060269)
82. Grant AV et al. 2013 Age-dependent association between pulmonary tuberculosis and common TOX variants in the 8q12-13 linkage region. Am. J. Hum. Genet. 92, 407-414. (doi:10.1016/j.ajhg. 2013.01.013)
83. Aliahmad P, Seksenyan A, Kaye J. 2012 The many roles of TOX in the immune system. Curr. Opin. Immunol. 24, 173-177. (doi:10.1016/j.coi.2011.12. 001)
84. Aliahmad P, Kadavallore A, de la Torre B, Kappes D, Kaye J. 2011 TOX is required for development of the CD4 T cell lineage gene program. J. Immunol. 187, 5931-5940. (doi:10.4049/jimmunol.1101474)
85. Aliahmad P, Kaye J. 2008 Development of all CD4 T lineages requires nuclear factor TOX. J. Exp. Med. 205, 245-256. (doi:10.1084/jem.20071944)
86. Thye T et al. 2010 Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nat. Genet. 42, 739-741. (doi:10.1038/ng.639)
87. Thye T et al. 2012 Common variants at 11p13 are associated with susceptibility to tuberculosis. Nat. Genet. 44, 257-259. (doi:10.1038/ng.1080)
88. Chimusa ER, Zaitlen N, Daya M, Moller M, van Helden PD, Mulder NJ, Price AL, Hoal EG. 2013 Genome-wide association study of ancestry-specific TB risk in the South African coloured population. Hum. Mol. Genet. 23, 796-809. (doi:10.1093/hmg/ ddt462)
89. Mahasirimongkol S et al. 2012 Genome-wide association studies of tuberculosis in Asians identify distinct at-risk locus for young tuberculosis. J. Hum. Genet. 57, 363-367. (doi:10.1038/jhg.2012.35)
90. Behr M, Schurr E, Gros P. 2010 TB: screening for responses to a vile visitor. Cell 140, 615-618. (doi:10.1016/j.cell.2010.02.030)
91. Tobin DM et al. 2010 The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717-730. (doi:10.1016/j. cell.2010.02.013)
92. Abel L, Casanova JL. 2000 Genetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritance. Am. J. Hum. Genet. 67, 274-277. (doi:10.1086/303033)
93. Altshuler DM et al. 2010 Integrating common and rare genetic variation in diverse human populations. Nature 467, 52-58. (doi:10.1038/nature09298)
94. Cirulli ET, Goldstein DB. 2010 Uncovering the roles of rare variants in common disease through wholegenome sequencing. Nat. Rev. Genet. 11, 415-425. (doi:10.1038/nrg2779)
95. Feinberg J et al. 2004 Bacillus Calmette Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4-and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur. J. Immunol. 34, 3276-3284. (doi:10.1002/eji. 200425221)
96. Di Pietrantonio T, Hernandez C, Girard M, Verville A, Orlova M, Belley A, Behr MA, Loredo-Osti JC, Schurr E. 2010 Strain-specific differences in the genetic control of two closely related mycobacteria. PLoS Pathog. 6, e1001169. (doi:10.1371/journal.ppat. 1001169)
97. Herb F et al. 2008 ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum. Mol. Genet. 17, 1052-1060. (doi:10.1093/ hmg/ddm378)
98. Intemann CD et al. 2009 Autophagy gene variant IRGM-261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 5, e1000577. (doi:10.1371/journal.ppat.1000577)
99. Nicol MP, Wilkinson RJ. 2008 The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 102, 955-965. (doi:10.1016/j.trstmh.2008.03.025)
100. Gregersen PK. 2012 Cell type-specific eQTLs in the human immune system. Nat. Genet. 44, 478-480. (doi:10.1038/ng.2258)
101. Pickrell JK et al. 2010 Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 464, 768-772. (doi:10. 1038/nature08872)
102. Berry MP et al. 2010 An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977. (doi:10. 1038/nature09247)
103. Cliff JM et al. 2013 Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect Dis. 207, 18-29. (doi:10.1093/infdis/jis499)
104. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, Walzl G, Kaufmann SH. 2011 Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12, 15-22. (doi:10.1038/gene.2010.51)
105. Ottenhoff TH et al. 2012 Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7, e45839. (doi:10.1371/journal.pone.0045839)
106. Bloom CI et al. 2013 Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 8, e70630. (doi:10.1371/ journal.pone.0070630)
107. Berry MP, Blankley S, Graham CM, Bloom CI, O'Garra A. 2013 Systems approaches to studying the immune response in tuberculosis. Curr. Opin. Immunol. 25, 579-587. (doi:10.1016/j.coi.2013.08.003)
108. Barreiro LB, Tailleux L, Pai AA, Gicquel B, Marioni JC, Gilad Y. 2012 Deciphering the genetic architecture of variation in the immune response to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 109, 1204-1209. (doi:10.1073/pnas. 1115761109)
109. Suarez-Alvarez B, Rodriguez RM, Fraga MF, Lopez-Larrea C. 2012 DNA methylation: a promising landscape for immune system-related diseases. Trends Genet. 28, 506-514. (doi:10.1016/j.tig.2012. 06.005)
110. Krueger F, Kreck B, Franke A, Andrews SR. 2012 DNA methylome analysis using short bisulfite sequencing data. Nat. Methods 9, 145-151. (doi:10.1038/nmeth.1828)
111. Laird PW. 2010 Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11, 191-203. (doi:10.1038/nrg2732)
112. Esterhuyse MM, Linhart HG, Kaufmann SH. 2012 Can the battle against tuberculosis gain from epigenetic research? Trends Microbiol. 20, 220-226. (doi:10.1016/j.tim.2012.03.002)
113. Chiacchiera F, Piunti A, Pasini D. 2013 Epigenetic methylations and their connections with metabolism. Cell Mol. Life Sci. 70, 1495-1508. (doi:10.1007/s00018-013-1293-5)
114. Kaelin Jr WG, McKnight SL. 2013 Influence of metabolism on epigenetics and disease. Cell 153, 56-69. (doi:10.1016/j.cell.2013.03.004)
115. Hawkins RD, Hon GC, Ren B. 2010 Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11, 476-486. (doi:10.1038/nrg2795)
116. Knight JC. 2013 Genomic modulators of the immune response. Trends Genet. 29, 74-83. (doi:10.1016/j.tig.2012.10.006)
117. O'Toole R. 2010 Experimental models used to study human tuberculosis. Adv. Appl. Microbiol. 71, 75-89. (doi:10.1016/S0065-2164(10)71003-0)
118. Flynn JL. 2006 Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 8, 1179-1188. (doi:10.1016/j.micinf.2005.10.033)
119. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. 2009 Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ. 87, 683-691. (doi:10.2471/BLT.08. 058453)
120. Oxlade O, Schwartzman K, Behr MA, Benedetti A, Pai M, Heymann J, Menzies D. 2009 Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int. J. Tuberc. Lung Dis. 13, 1238-1246.
121. Oxlade O, Schwartzman K, Benedetti A, Pai M, Heymann J, Menzies D. 2011 Developing a tuberculosis transmission model that accounts for changes in population health. Med. Decis. Making 31, 53-68. (doi:10.1177/0272989X10369001)
122. Lienhardt C, Glaziou P, Uplekar M, Lonnroth K, Getahun H, Raviglione M. 2012 Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol. 10, 407-416. (doi:10.1038/ nrmicro2797)
123. Ota MO et al. 2011 Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med. 3, 88ra56. (doi:10.1126/scitranslmed.3002461)
124. Tameris MD et al. 2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028. (doi:10.1016/S0140-6736(13)60177-4)
125. Medina E, North RJ. 1999 Genetically susceptible mice remain proportionally more susceptible to tuberculosis after vaccination. Immunology 96, 16-21. (doi:10.1046/j.1365-2567.1999.00663.x)
126. Verver S et al. 2005 Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171, 1430-1435. (doi:10.1164/rccm.200409-1200OC)
127. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, Ernst JD, Gagneux S. 2010 Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 42, 498-503. (doi:10.1038/ng.590)